A detailed history of Squarepoint Ops LLC transactions in Cabaletta Bio, Inc. stock. As of the latest transaction made, Squarepoint Ops LLC holds 156,995 shares of CABA stock, worth $379,927. This represents 0.0% of its overall portfolio holdings.

Number of Shares
156,995
Previous 315,379 50.22%
Holding current value
$379,927
Previous $2.36 Million 68.59%
% of portfolio
0.0%
Previous 0.0%

Shares

12 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 14, 2024

SELL
$3.94 - $8.24 $624,032 - $1.31 Million
-158,384 Reduced 50.22%
156,995 $741,000
Q2 2024

Aug 14, 2024

BUY
$7.22 - $18.82 $1.97 Million - $5.14 Million
272,948 Added 643.27%
315,379 $2.36 Million
Q1 2024

May 15, 2024

BUY
$16.79 - $25.38 $315,618 - $477,093
18,798 Added 79.54%
42,431 $723,000
Q4 2023

Feb 14, 2024

BUY
$12.21 - $23.36 $161,342 - $308,679
13,214 Added 126.83%
23,633 $536,000
Q2 2023

Aug 14, 2023

SELL
$7.65 - $13.95 $356,834 - $650,697
-46,645 Reduced 81.74%
10,419 $134,000
Q1 2023

May 15, 2023

BUY
$7.08 - $12.62 $404,013 - $720,147
57,064 New
57,064 $471,000
Q2 2021

Aug 16, 2021

SELL
$7.2 - $11.73 $201,067 - $327,571
-27,926 Closed
0 $0
Q1 2021

May 17, 2021

SELL
$10.39 - $14.53 $26,276 - $36,746
-2,529 Reduced 8.3%
27,926 $310,000
Q4 2020

Feb 16, 2021

SELL
$9.81 - $15.8 $224,099 - $360,935
-22,844 Reduced 42.86%
30,455 $380,000
Q3 2020

Nov 16, 2020

SELL
$9.71 - $14.41 $12,176 - $18,070
-1,254 Reduced 2.3%
53,299 $578,000
Q2 2020

Aug 14, 2020

BUY
$6.39 - $11.28 $268,482 - $473,940
42,016 Added 335.14%
54,553 $608,000
Q1 2020

May 15, 2020

BUY
$6.0 - $18.67 $75,222 - $234,065
12,537 New
12,537 $92,000

Others Institutions Holding CABA

About Cabaletta Bio, Inc.


  • Ticker CABA
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 29,014,000
  • Market Cap $70.2M
  • Description
  • Cabaletta Bio, Inc., a clinical-stage biotechnology company, focuses on the discovery and development of engineered T cell therapies for patients with B cell-mediated autoimmune diseases. Its proprietary technology utilizes chimeric autoantibody receptor (CAAR) T cells that are designed to selectively bind and eliminate B cells, which produce di...
More about CABA
Track This Portfolio

Track Squarepoint Ops LLC Portfolio

Follow Squarepoint Ops LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Squarepoint Ops LLC, based on Form 13F filings with the SEC.

News

Stay updated on Squarepoint Ops LLC with notifications on news.